Description
Renal dysfunction is a significant concern for patients with liver cirrhosis, affecting nearly 50% of those hospitalised and leading to various complications that can reduce survival rates. Recently, the diagnostic criteria for acute kidney injury (AKI) and hepatorenal syndrome (HRS) have been updated to better capture the diversity and incidence of these conditions in cirrhotic patients.
This episode of EASL Studio:
- Explores the updated definitions and standardisation of AKI in the context of cirrhosis.
- Reviews recent clinical trials, including ATTIRE and CONFIRM, and their implications for patient care.
- Provides a critical analysis of current and emerging strategies for managing renal dysfunction in cirrhosis.
Faculty
- Debbie Shawcross (Moderator)
- Pere Gines (Faculty)
- Salvatore Piano (Faculty)
- Florence Wong (Faculty)
Related episodes
- EASL Studio from EASL Congress 2024: Deciphering the drivers of cirrhosis decompensation: Opportunities for intervention and prevention
- EASL Studio S6E8: Is there a role for measuring blood ammonia in patients with cirrhosis?
- EASL Studio S6E5: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?
- EASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?
- EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address them
- EASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?
ℹ️ Please click here to watch this EASL Studio episode.
This episode is sponsored by Mallinckrodt Pharmaceuticals. Mallinckrodt Pharmaceuticals have had no input into the content of this EASL Studio episode.
